The patient, our priority

30 years of development for the benefit of patients

Having worked in oncology for nearly 30 years, the Group has become a benchmark for health care professionals and a powerful ally of cancer patients, thanks in particular to its major advances in oncology:

  • Discovery and marketing of drugs containing plant-based active ingredients
  • Development of oral chemotherapy, which improves the comfort of the treatment for both patients and caregivers
  • Treatments for diseases for which there were virtually no solutions, such as adjuvant therapy for non-small cell lung cancer and second-line treatment for bladder cancer, and intravenous conditioning treatment for bone marrow transplants (especially for pediatric care)
  • Launch of the OneSmile study for preventing and relieving the skin disorders caused by cancer treatments

Oral chemotherapy

Focus on... oral chemotherapy  

Chemotherapy drugs in the form of tablets or gel capsules, which can be swallowed rather than injected intravenously.

The development of oral chemotherapy represents a major improvement in the treatment arsenal. This form of treatment improves comfort, not just for the caregivers but most importantly for the patient. Oral chemotherapy makes it easier to treat patients in an outpatient setting and allows them greater flexibility and freedom.

The development of orally-administered forms - as opposed to intravenously - also secured our laboratory's place in the history of oncology. Olivier Provendier, director of Global Oncology Operations.

Improve the patient's life

Focus on... One Smile of Laboratoires Dermatologiques Avène

(ONco Education and Skin side effects MInimized for Living Even better)
A project launched in 2015 by Avène Dermatological Laboratories for understanding, preventing, and relieving the skin disorders caused by cancer treatments.

This project is aimed at men and women who are battling cancer and who are suffering the unwanted side effects of their treatment, which are often visible on the skin.

One Smile provides information, for both patients and professionals, about the specific cutaneous effects of each type of treatment, as well as about the best care for relieving those side effects and improving quality of life.
Discover the OneSmile project

The "Echappée rose"

The association "Tous contre le cancer"(Everybody against cancer) has decided to meet women vulnerable to cancer and bring them well-being and beauty wherever they are, in hospitals from October 5 to November 8, 2017. It is more precisely on the car parks of the hospitals that the association had given the appointment, in a Bus arranged in true "living room well-being".

Translational medicine

Focus on... translational medicine  

A concept that has developed over the past twenty years, providing the missing link between fundamental and clinical research. It allows patients to benefit more quickly from diagnostic and therapeutic advances and innovations.

In order to be able to progress faster and more confidently from fundamental research to proof of concept and finally to a drug that can be administered to patients, we are going to be focusing heavily on translational medicine. Our physical presence at the Toulouse Oncopole campus in the Midi-Pyrénées region reflects our commitment to this field of research. We owe this establishment to our founder, Mr. Pierre Fabre, who was highly attached to public-private collaboration and to the link between research and patients.

According to Mr. Pierre Fabre, the proximity of a hospital, its patients, its researchers, and caregivers to a research laboratory can only accelerate the development of new treatments.

Today, our Group works in close collaboration with the Toulouse University Cancer Institute (IUCT-O), a true frame of reference as regards its oncology education, research, and care, which opened in 2003. This health care establishment, which is also perfectly designed for research, is located right next to our own research center, and represents a major opportunity for developing future molecules for patients.